Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
AMIODARONE HYDROCHLORIDE
NU-PHARM INC
C01BD01
AMIODARONE
200MG
TABLET
AMIODARONE HYDROCHLORIDE 200MG
ORAL
30/100/500/1000
Prescription
CLASS III ANTIARRYTHMICS
Active ingredient group (AIG) number: 0118593001; AHFS:
CANCELLED (UNRETURNED ANNUAL)
2018-03-28
Page 1 of 71 PRODUCT MONOGRAPH PR NU-AMIODARONE (AMIODARONE HYDROCHLORIDE TABLETS BP) 200 MG ANTIARRHYTHMIC AGENT NU-PHARM INC. DATE OF PREPARATION: 50 MURAL ST., UNITS 1 & 2 OCTOBER 15, 2009 RICHMOND HILL, ONTARIO L4B 1E4 CONTROL#: 133376 Page 2 of 71 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION................................................................3 SUMMARY PRODUCT INFORMATION.................................................................................3 INDICATIONS AND CLINICAL USE.......................................................................................3 CONTRAINDICATIONS..........................................................................................................4 WARNINGS AND PRECAUTIONS.........................................................................................4 ADVERSE REACTIONS .......................................................................................................19 DRUG INTERACTIONS........................................................................................................25 DOSAGE AND ADMINISTRATION.......................................................................................29 OVERDOSAGE.....................................................................................................................31 ACTION AND CLINICAL PHARMACOLOGY .......................................................................32 STORAGE AND STABILITY .................................................................................................36 DOSAGE FORMS, COMPOSITION AND PACKAGING ......................................................37 PART II: SCIENTIFIC INFORMATION.....................................................................................38 PHARMACEUTICAL INFORMATION...................................................................................38 CLINICAL TRIALS.................................................................................................................39 DETAILED PHARMACOLOGY... Կարդացեք ամբողջական փաստաթուղթը